Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists

被引:23
作者
Fujisawa, T [1 ]
Adachi, K [1 ]
Komazawa, Y [1 ]
Mihara, T [1 ]
Azumi, T [1 ]
Katsube, T [1 ]
Furuta, K [1 ]
Kazumori, H [1 ]
Kinoshita, Y [1 ]
机构
[1] Shimane Univ, Sch Med, Dept Gastroenterol & Hepatol, Izumo, Shimane 6938501, Japan
关键词
D O I
10.1111/j.1365-2036.2004.02147.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The attenuated anti-secretory activity of H2 receptor antagonists (H2RA) during continuous administration is referred to as the tolerance phenomenon. However, it is not clarified whether Helicobacter pylori infection affects the occurrence of tolerance to H2RA. It is also not clarified whether the tolerance phenomenon occurs to a new H2RA, lafutidine. Aim: To investigate the occurrence of the tolerance phenomenon in subjects with and without H. pylori infection during the continuous administration of lafutidine and famotidine. Subjects and Methods: Subjects were 20 healthy male volunteers (seven H. pylori positive and 13 H. pylori negative cases). All subjects were examined by ambulatory intragastric pH monitoring five times without medication, on the first and 15th day of the administration of 20 mg b.d. famotidine and 10 mg b.d. lafutidine in a cross-over fashion. Results: The tolerance phenomenon was not observed in H. pylori-positive subjects during the 15-day-long administration of both H2RAs. In contrast, the tolerance phenomenon was observed in H. pylori negative subjects, which has been previously reported. Conclusions: This study demonstrated that H. pylori infection affects the tolerance phenomenon during continuous administration of H2RAs.
引用
收藏
页码:559 / 565
页数:7
相关论文
共 35 条
[1]   Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection [J].
Adachi, K ;
Fujishiro, H ;
Mihara, T ;
Komazawa, Y ;
Kinoshita, Y .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2003, 18 (02) :168-171
[2]  
Adachi K, 2000, ALIMENT PHARM THERAP, V14, P919
[3]   Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen [J].
Adachi, K ;
Ishihara, S ;
Hashimoto, T ;
Hirakawa, K ;
Ishimura, N ;
Niigaki, M ;
Kaji, T ;
Kawamura, A ;
Sato, H ;
Fujishiro, H ;
Hattori, S ;
Watanabe, M ;
Kinoshita, Y .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (08) :1187-1191
[4]  
BERLIN RG, 1991, ALIMENT PHARM THERAP, V5, P161
[5]   OMEPRAZOLE IN THE LONG-TERM MANAGEMENT OF PATIENTS WITH ACID-RELATED DISEASES RESISTANT TO RANITIDINE [J].
BRUNNER, G ;
CREUTZFELDT, W .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1989, 24 :101-105
[6]   How does Helicobacter pylori cause mucosal damage? Its effect on acid and gastrin physiology [J].
Calam, J ;
Gibbons, A ;
Healey, ZV ;
Bliss, P ;
Arebi, N .
GASTROENTEROLOGY, 1997, 113 (06) :S43-S49
[7]   PREVENTION OF DUODENAL-ULCER RELAPSE BY LONG-TERM TREATMENT WITH OMEPRAZOLE [J].
FESTEN, HPM .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1994, 29 :39-41
[8]   Problems related to acid rebound and tachyphylaxis [J].
Gillen, D ;
McColl, KEL .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2001, 15 (03) :487-495
[9]   EPIDEMIOLOGY OF HELICOBACTER-PYLORI IN AN ASYMPTOMATIC POPULATION IN THE UNITED-STATES - EFFECT OF AGE, RACE, AND SOCIOECONOMIC-STATUS [J].
GRAHAM, DY ;
MALATY, HM ;
EVANS, DG ;
EVANS, DJ ;
KLEIN, PD ;
ADAM, E .
GASTROENTEROLOGY, 1991, 100 (06) :1495-1501
[10]   PHARMACOLOGICAL ASPECTS OF ACID-SECRETION [J].
HIRSCHOWITZ, BI ;
KEELING, D ;
LEWIN, M ;
OKABE, S ;
PARSONS, M ;
SEWING, K ;
WALLMARK, B ;
SACHS, G .
DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (02) :S3-S23